Report Library
All ReportsDatamonitor Acute Myelogenous Leukemia (AML) KOL Interview
August 19, 2016
Datamonitor interviewed three oncology specialists to determine the physicians'
views on marketed and pipeline therapies for Acute Myelogenous Leukemia. Two physicians were based in the US (Greater Midwest and
Greater Boston areas) and one in the UK. The three interviews were combined into a single report.
If you are a KOL Insight Subscriber, please access the first, second and third interview from our KOL Insight portal (Subscribers only).
Highlights
For our disclosures, please read the Biomedtracker Research Standards.
If you are a KOL Insight Subscriber, please access the first, second and third interview from our KOL Insight portal (Subscribers only).
Highlights
- Prescribing habits and treatment strategies for AML.
- Treatment challenges and unmet needs in AML.
- Late-stage pipeline therapies including treatments for patients not suited for high-intensity induction therapy and patients in the relapsed setting: midostaurin, Vyxeos, SGN-33, guadecitabine, IDH1 and IDH2 inhibitors, idasanutlin, and venetoclax.
- Outlook of CAR-T therapy for AML.
- Future treatment of AML.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Acute Myelogenous Leukemia (AML) |
Additional Resources: